Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization

Robert C Rennert; Usman Khan; Jiri Bartek; Stephen B Tatter; Melvin Field; Brian Toyota; Peter E Fecci; Kevin Judy; Alireza M Mohammadi; Patrick Landazuri; Andrew E Sloan; Albert H Kim; Eric C Leuthardt; Clark C Chen

doi:10.1093/neuros/nyz141

Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization

Robert C Rennert, Usman Khan, Jiri Bartek, Stephen B Tatter, Melvin Field, Brian Toyota, Peter E Fecci, Kevin Judy, Alireza M Mohammadi, Patrick Landazuri, Andrew E Sloan, Albert H Kim, Eric C Leuthardt, Clark C Chen

Department of Neurosurgery

Abstract

BACKGROUND: Stereotactic laser ablation (SLA) has demonstrated potential utility for a spectrum of difficult to treat neurosurgical pathologies in multiple small and/or retrospective single-institutional series. Here, we present the safety profile of SLA of intracranial lesions from the Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN; Monteris Medical) multi-institutional, international prospective observational registry.

OBJECTIVE: To determine the procedural safety of SLA for intracranial lesions.

METHODS: Prospective procedural safety and hospitalization data from the first 100 treated LAANTERN patients was collected and analyzed.

RESULTS: Mean age and baseline Karnofsky Performance Status (KPS) were 51(± 17) yr and 83(± 15), respectively. In total, 81.2% of patients had undergone prior surgical or radiation treatment. Most patients had a single lesion (79%) ablated through 1 burr hole (1.2 ± 0.7 per patient), immediately following a lesion biopsy. In total, >90% of the lesion was ablated in 72% of treated lesions. Average total procedural time was 188.2 ± 69.6 min, and average blood loss was 17.7 ± 55.6 ccs. The average length of intensive care unit (ICU) and hospital stays before discharge were 38.1 ± 62.7 h and 61.1 ± 87.2 h, respectively. There were 5 adverse events (AEs) attributable to SLA (5/100; 5%). After the procedure, 84.8% of patients were discharged home. There was 1 mortality within 30 d of the procedure (1/100; 1%), which was not attributable to SLA.

CONCLUSION: SLA is a safe, minimally invasive procedure with favorable postprocedural ICU and hospital utilization profiles.

Original language	English
Journal	Neurosurgery
Volume	86
Issue number	4
Pages (from-to)	538-547
Number of pages	10
ISSN	0069-4827
DOIs	https://doi.org/10.1093/neuros/nyz141
Publication status	Published - 1 Apr 2020

Access to Document

10.1093/neuros/nyz141

Cite this

Rennert, R. C., Khan, U., Bartek, J., Tatter, S. B., Field, M., Toyota, B., Fecci, P. E., Judy, K., Mohammadi, A. M., Landazuri, P., Sloan, A. E., Kim, A. H., Leuthardt, E. C., & Chen, C. C. (2020). Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization. Neurosurgery, 86(4), 538-547. https://doi.org/10.1093/neuros/nyz141

Rennert, RC, Khan, U, Bartek, J, Tatter, SB, Field, M, Toyota, B, Fecci, PE, Judy, K, Mohammadi, AM, Landazuri, P, Sloan, AE, Kim, AH, Leuthardt, EC & Chen, CC 2020, 'Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization', Neurosurgery, vol. 86, no. 4, pp. 538-547. https://doi.org/10.1093/neuros/nyz141

@article{107899ff1d814aa890af6d1aa1aa1c35,

title = "Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization",

abstract = "BACKGROUND: Stereotactic laser ablation (SLA) has demonstrated potential utility for a spectrum of difficult to treat neurosurgical pathologies in multiple small and/or retrospective single-institutional series. Here, we present the safety profile of SLA of intracranial lesions from the Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN; Monteris Medical) multi-institutional, international prospective observational registry.OBJECTIVE: To determine the procedural safety of SLA for intracranial lesions.METHODS: Prospective procedural safety and hospitalization data from the first 100 treated LAANTERN patients was collected and analyzed.RESULTS: Mean age and baseline Karnofsky Performance Status (KPS) were 51(± 17) yr and 83(± 15), respectively. In total, 81.2% of patients had undergone prior surgical or radiation treatment. Most patients had a single lesion (79%) ablated through 1 burr hole (1.2 ± 0.7 per patient), immediately following a lesion biopsy. In total, >90% of the lesion was ablated in 72% of treated lesions. Average total procedural time was 188.2 ± 69.6 min, and average blood loss was 17.7 ± 55.6 ccs. The average length of intensive care unit (ICU) and hospital stays before discharge were 38.1 ± 62.7 h and 61.1 ± 87.2 h, respectively. There were 5 adverse events (AEs) attributable to SLA (5/100; 5%). After the procedure, 84.8% of patients were discharged home. There was 1 mortality within 30 d of the procedure (1/100; 1%), which was not attributable to SLA.CONCLUSION: SLA is a safe, minimally invasive procedure with favorable postprocedural ICU and hospital utilization profiles.",

author = "Rennert, {Robert C} and Usman Khan and Jiri Bartek and Tatter, {Stephen B} and Melvin Field and Brian Toyota and Fecci, {Peter E} and Kevin Judy and Mohammadi, {Alireza M} and Patrick Landazuri and Sloan, {Andrew E} and Kim, {Albert H} and Leuthardt, {Eric C} and Chen, {Clark C}",

note = "{\textcopyright} Congress of Neurological Surgeons 2019.",

year = "2020",

month = apr,

day = "1",

doi = "10.1093/neuros/nyz141",

language = "English",

volume = "86",

pages = "538--547",

journal = "Neurosurgery",

issn = "0069-4827",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

TY - JOUR

T1 - Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN)

T2 - Procedural Safety and Hospitalization

AU - Rennert, Robert C

AU - Khan, Usman

AU - Bartek, Jiri

AU - Tatter, Stephen B

AU - Field, Melvin

AU - Toyota, Brian

AU - Fecci, Peter E

AU - Judy, Kevin

AU - Mohammadi, Alireza M

AU - Landazuri, Patrick

AU - Sloan, Andrew E

AU - Kim, Albert H

AU - Leuthardt, Eric C

AU - Chen, Clark C

PY - 2020/4/1

Y1 - 2020/4/1

N2 - BACKGROUND: Stereotactic laser ablation (SLA) has demonstrated potential utility for a spectrum of difficult to treat neurosurgical pathologies in multiple small and/or retrospective single-institutional series. Here, we present the safety profile of SLA of intracranial lesions from the Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN; Monteris Medical) multi-institutional, international prospective observational registry.OBJECTIVE: To determine the procedural safety of SLA for intracranial lesions.METHODS: Prospective procedural safety and hospitalization data from the first 100 treated LAANTERN patients was collected and analyzed.RESULTS: Mean age and baseline Karnofsky Performance Status (KPS) were 51(± 17) yr and 83(± 15), respectively. In total, 81.2% of patients had undergone prior surgical or radiation treatment. Most patients had a single lesion (79%) ablated through 1 burr hole (1.2 ± 0.7 per patient), immediately following a lesion biopsy. In total, >90% of the lesion was ablated in 72% of treated lesions. Average total procedural time was 188.2 ± 69.6 min, and average blood loss was 17.7 ± 55.6 ccs. The average length of intensive care unit (ICU) and hospital stays before discharge were 38.1 ± 62.7 h and 61.1 ± 87.2 h, respectively. There were 5 adverse events (AEs) attributable to SLA (5/100; 5%). After the procedure, 84.8% of patients were discharged home. There was 1 mortality within 30 d of the procedure (1/100; 1%), which was not attributable to SLA.CONCLUSION: SLA is a safe, minimally invasive procedure with favorable postprocedural ICU and hospital utilization profiles.

AB - BACKGROUND: Stereotactic laser ablation (SLA) has demonstrated potential utility for a spectrum of difficult to treat neurosurgical pathologies in multiple small and/or retrospective single-institutional series. Here, we present the safety profile of SLA of intracranial lesions from the Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN; Monteris Medical) multi-institutional, international prospective observational registry.OBJECTIVE: To determine the procedural safety of SLA for intracranial lesions.METHODS: Prospective procedural safety and hospitalization data from the first 100 treated LAANTERN patients was collected and analyzed.RESULTS: Mean age and baseline Karnofsky Performance Status (KPS) were 51(± 17) yr and 83(± 15), respectively. In total, 81.2% of patients had undergone prior surgical or radiation treatment. Most patients had a single lesion (79%) ablated through 1 burr hole (1.2 ± 0.7 per patient), immediately following a lesion biopsy. In total, >90% of the lesion was ablated in 72% of treated lesions. Average total procedural time was 188.2 ± 69.6 min, and average blood loss was 17.7 ± 55.6 ccs. The average length of intensive care unit (ICU) and hospital stays before discharge were 38.1 ± 62.7 h and 61.1 ± 87.2 h, respectively. There were 5 adverse events (AEs) attributable to SLA (5/100; 5%). After the procedure, 84.8% of patients were discharged home. There was 1 mortality within 30 d of the procedure (1/100; 1%), which was not attributable to SLA.CONCLUSION: SLA is a safe, minimally invasive procedure with favorable postprocedural ICU and hospital utilization profiles.

U2 - 10.1093/neuros/nyz141

DO - 10.1093/neuros/nyz141

M3 - Journal article

C2 - 31076762

SN - 0069-4827

VL - 86

SP - 538

EP - 547

JO - Neurosurgery

JF - Neurosurgery

IS - 4

ER -

Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization

Abstract

Access to Document

Fingerprint

Cite this